Targets › PPARG
13 programs from 13 companies in 38 trials: 11 Phase 2, 10 Phase 3, 10 Phase 1, 7 Phase 4; Oncology, Gastroenterology, Metabolic and endocrine; next expected readout Dec 2026.
Ligand-activated transcription factor that forms obligate heterodimers with the retinoic acid receptor and acts as a key regulator of biological processes, such as adipocyte differentiation, lipid metabolism, glucose homeostasis and beta-oxidation of fatty acids. Activated by lipid ligands: binds peroxisome proliferators, such as hypolipidemic drugs, and fatty acids, such as prostaglandin J2 metabolites. (UniProt, P37231)
Open in Phaseline: the race on PPARG, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Dong Wha Pharmaceutical | Pioglitazone Peroxisome proliferator-activated receptor gamma agonist | PPARG | Phase 4 | Type2diabetes | – |
| Zydus Therapeutics | Saroglitazar Peroxisome proliferator-activated receptor alpha agonist; Peroxisome proliferator-activated receptor gamma agonist | PPARA, PPARG | Phase 3 | Primary Biliary Cholangitis; Hepatic Impairment; Cholestatic Liver Disease | Dec 2026 |
| Minoryx Therapeutics | Leriglitazone Peroxisome proliferator-activated receptor gamma agonist | PPARG | Phase 3 | Cerebral Adrenoleukodystrophy (cALD) | May 2027 |
| Inventiva Pharma | Lanifibranor (IVA337) Peroxisome proliferator-activated receptor agonist | PPARG, PPARA, PPARD | Phase 3 | NASH - Nonalcoholic Steatohepatitis | Sep 2027 |
| Assistance Publique - Hôpitaux de Paris | Bezafibrate Peroxisome proliferator-activated receptor agonist | PPARG, PPARA, PPARD | Phase 3 | BPC | Dec 2027 |
| The First Affiliated Hospital of Xiamen University | Chiglitazar Peroxisome proliferator-activated receptor agonist | PPARG, PPARA, PPARD | Phase 2 | Relapsed or Refractory Acute Myeloid Leukemia; Acute Myeloid Leukemia | Dec 2026 |
| University of Minnesota | pioglitazone-metformin PPAR-gamma agonist combined with AMP-activated protein kinase activator | PPARG | Phase 2 | Oral Leukoplakia | Jul 2027 |
| AHS Cancer Control Alberta | Mesalamine Arachidonate 5-lipoxygenase inhibitor; Peroxisome proliferator-activated receptor gamma agonist; Cyclooxygenase inhibitor | ALOX5, PPARG, PTGS2, PTGS1 | Phase 2 | Immune-related Adverse Event | Aug 2027 |
| Shanghai Jiao Tong University School of Medicine | Chiglitazar Peroxisome proliferator-activated receptor agonist | PPARG, PPARA, PPARD | Phase 2 | MASH - Metabolic Dysfunction-Associated Steatohepatitis | Dec 2030 |
| Dan Zandberg | Rosiglitazone Peroxisome proliferator-activated receptor-gamma (PPARγ) agonist | PPARG | Phase 2 | Melanoma | Apr 2032 |
| Ann-Sofie Backman | Mesalamine Arachidonate 5-lipoxygenase inhibitor; Peroxisome proliferator-activated receptor gamma agonist; Cyclooxygenase inhibitor | ALOX5, PPARG, PTGS2, PTGS1 | Phase 2 | Lynch Syndrome | Sep 2032 |
| Flare Therapeutics | FX-909 PPARG transcription inhibitor (basal- and ligand-activated) | PPARG | Phase 1 | Advanced Urothelial Carcinoma | Oct 2027 |
| Boryung Pharmaceutical | Pioglitazone Peroxisome proliferator-activated receptor gamma agonist | PPARG | Phase 1 | Diabetes Mellitus; Diabete Mellitus; Infertility Treatment; Type 2 Diabetes … | – |
Primary Biliary Cholangitis (3) BPC (2) Type 2 Diabetes (2) Hepatic Impairment (1) Cholestatic Liver Disease (1) Oral Leukoplakia (1) Advanced Urothelial Carcinoma (1) Melanoma (1) MASH - Metabolic Dysfunction-Associated Steatohepatitis (1) Relapsed or Refractory Acute Myeloid Leukemia (1) Acute Myeloid Leukemia (1) Diabetes Mellitus (1)
small molecule (11), mixed (2)
Assistance Publique - Hôpitaux de Paris (1) Zydus Therapeutics (1) University of Minnesota (1) Flare Therapeutics (1) Dan Zandberg (1) Shanghai Jiao Tong University School of Medicine (1) The First Affiliated Hospital of Xiamen University (1) Boryung Pharmaceutical (1) Minoryx Therapeutics (1) Dong Wha Pharmaceutical (1) Ann-Sofie Backman (1) Inventiva Pharma (1) AHS Cancer Control Alberta (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.